BMC Infectious Diseases

Table 2 Ligation strength analysis of Tg-toxofilin for MHC class II molecules using SYFPEITHI^a

From: Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii

MHC II Allele^b	Start-Stop^c	Sequence	Percent: e Rank^d
HLA-DRB1*01:01	91-105	LQTVHQLGAVALTPE	0.39
HLA-DRB1*01:01	9-23	LAAFLLLIVGSLLT	0.42
H2-IAb	78-92	EERLIAGQAKAAALQ	3.04
H2-IAb	96-110	QLGAVALTPEQAKAA	6.58
H2-IAd	178-192	HYHVTKQAALAGQIL	0.13
H2-IAd	231-245	QHASQLKKVGAMPSS	0.62
H2-IEd	169-183	KARKLFQRRHYHVTK	13.80
H2-IEd	28-42	VQLSEGMKRLSMRGR	21.98

^aThe prediction was run for three times
^bH2-IAb, H2-IAd and H2-IEd alleles are mouse MHC class II molecules; the HLADRB1*01:01 allele is a human MHC class II molecule
^cWe chose 15 amino acids for analysis each time
^dLow percentile = high level binding, high percentile = low level binding

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com